A Phase IB Dose-Escalation Study of Pemetrexed and AUY922 in Previously-Treated Patients With Metastatic Non-Squamous, Non-Small Cell Lung Cancer
Phase of Trial: Phase I
Latest Information Update: 24 Apr 2019
At a glance
- Drugs Luminespib (Primary) ; Pemetrexed
- Indications Non-small cell lung cancer
- Focus Adverse reactions
- 22 Apr 2019 Status changed from active, no longer recruiting to completed.
- 26 Sep 2018 Results (n=13) presented at the 19th World Conference on Lung Cancer
- 23 Aug 2013 Planned End Date changed from 1 Mar 2015 to 1 Mar 2016 as reported by ClinicalTrials.gov.